Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lasker Award: Priority Claim

Lasker Award: Priority Claim To the Editor:— I want to protest officially the recognition that has been accorded Dr. Nathan S. Kline's role in the development of monoamine oxidase inhibitors, and specifically iproniazid, for the treatment of depression. This matter becomes currently urgent because of Dr. Kline's recent acceptance of the Lasker Award and the publication in The Journal of his paper "The Practical Management of Depression," presented as a result of this (190:732 [Nov 23] 1964). Neither the terms of the award nor the paper recognize that my role was primary in the development and administration of this drug for this purpose. There can be no doubt that intellectual dishonesty is involved here. I am enclosing a substantiating reprint (Saunders, J.C.: Treatment of Hospitalized Depressed and Schizophrenic Patients With Monoamine Oxidase Inhibitors: Including Reflections on Pargyline, Ann NY Acad Sci 107:1081 [July 8] 1963) and a copy of my letter of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Lasker Award: Priority Claim

JAMA , Volume 191 (10) – Mar 8, 1965

Lasker Award: Priority Claim

Abstract



To the Editor:—
I want to protest officially the recognition that has been accorded Dr. Nathan S. Kline's role in the development of monoamine oxidase inhibitors, and specifically iproniazid, for the treatment of depression. This matter becomes currently urgent because of Dr. Kline's recent acceptance of the Lasker Award and the publication in The Journal of his paper "The Practical Management of Depression," presented as a result of...
Loading next page...
 
/lp/american-medical-association/lasker-award-priority-claim-d3ntMjmcyz

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1965 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1965.03080100083031
Publisher site
See Article on Publisher Site

Abstract

To the Editor:— I want to protest officially the recognition that has been accorded Dr. Nathan S. Kline's role in the development of monoamine oxidase inhibitors, and specifically iproniazid, for the treatment of depression. This matter becomes currently urgent because of Dr. Kline's recent acceptance of the Lasker Award and the publication in The Journal of his paper "The Practical Management of Depression," presented as a result of this (190:732 [Nov 23] 1964). Neither the terms of the award nor the paper recognize that my role was primary in the development and administration of this drug for this purpose. There can be no doubt that intellectual dishonesty is involved here. I am enclosing a substantiating reprint (Saunders, J.C.: Treatment of Hospitalized Depressed and Schizophrenic Patients With Monoamine Oxidase Inhibitors: Including Reflections on Pargyline, Ann NY Acad Sci 107:1081 [July 8] 1963) and a copy of my letter of

Journal

JAMAAmerican Medical Association

Published: Mar 8, 1965

There are no references for this article.